Krazati (Adagrasib) for Lung Cancer

Overview
Krazati is a brand name for the drug Adagrasib, which is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer (NSCLC) in adults. Specifically, it is used as a single agent for individuals with KRAS G12C-mutated locally advanced or metastatic NSCLC who have already received at least one prior systemic therapy. This mutation must be identified using an FDA-approved test. Krazati is also known by its drug name, adagrasib.

Adagrasib is a KRAS inhibitor. It works by specifically targeting and inhibiting the activity of the KRAS G12C mutation, which is found in some types of cancer cells. By blocking this mutation, Krazati can help slow or stop the growth of cancer cells, leading to a reduction in tumor size and progression.

How do I take it?
Prescribing information states that Krazati is taken orally as a tablet. For the treatment of NSCLC, the recommended dosage schedule is twice daily. Individuals should swallow the tablets whole, with or without food, and continue the treatment as prescribed. It is important to take Krazati exactly as prescribed by a health care provider.

Side effects
Common side effects of Krazati in treating individuals with NCSLC include nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity (liver damage), renal impairment (kidney damage), edema (swelling), dyspnea (shortness of breath), and decreased appetite. Laboratory tests may also show changes such as decreased lymphocytes (a type of white blood cell), decreased hemoglobin (a protein in red blood cells), increased liver enzymes like alanine aminotransferase and aspartate aminotransferase, hypokalemia (low potassium levels), hyponatremia (low sodium levels), increased lipase (an enzyme related to pancreas function), decreased leukocytes (another type of white blood cell), decreased neutrophils (a type of immune cell), and increased alkaline phosphatase (an enzyme related to liver and bone health).

Rare but serious side effects may include gastrointestinal adverse reactions like severe diarrhea, nausea, and vomiting; QTc interval prolongation (a heart rhythm issue); hepatotoxicity; and interstitial lung disease or pneumonitis (inflammation of lung tissue). 

For more information about this treatment, visit:

Label: Krazati — Adagrasib Tablet, Coated — DailyMed

Krazati — Drugs.com